Skip to Content

IL-17i – A New Direction in Treating Psoriatic Arthritis Patients with Multiple Comorbidities?

Many psoriatic arthritis (PsA) patients have comorbidities, and previous treatment with TNF-alpha inhibitors (TNFi) is less effective for them than PsA without comorbidities. A new study from the Parker Institute in Copenhagen has investigated whether this also applies to PsA patients receiving their first IL-17 inhibitor (IL-17i) treatment.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top